Bristol Myers Squibb (BMY) reported third-quarter 2026 revenue of $13.1 billion, up 7% from the prior-year period. GAAP net earnings were $2.162 billion, with diluted earnings per share of $1.05.
The company raised its 2026 revenue outlook to approximately $49.75 billion to $50.25 billion. Growth Portfolio revenue increased 12% to $7.7 billion, while Legacy Portfolio revenue increased 1% to $5.4 billion.
- GAAP basic EPS was $1.06, compared with $1.08 a year earlier.
- U.S. revenue rose 9% to $9.1 billion, while international revenue increased 3% to $4.0 billion.
- Eliquis worldwide revenue increased 25% to $4.69 billion.
- The FDA approved Zenbexus in August for certain adult patients with multiple myeloma.
- Updated full-year non-GAAP EPS guidance is $6.35 to $6.55 per share.
